PURPOSE: The aim of this study was to determine the range of absorbed doses delivered to thyroid remnants, blood, and red marrow from fixed administrations of radioiodine and to ascertain whether the success of ablation is more dependent on these absorbed doses than on the administered activity. METHODS: Twenty-three patients received 3,000 MBq radioiodine following near-total thyroidectomy. The maximum absorbed dose to remnants was calculated from subsequent single photon emission tomography scans. Absorbed doses delivered to blood and red marrow were calculated from blood samples and from whole-body retention measurements. The protein bound iodine (PBI) was also calculated. RESULTS: Maximum absorbed doses to thyroid remnants ranged from 7 to 570 Gy. Eighteen of the 23 patients had a successful ablation. A significant difference was seen between the absorbed doses delivered to thyroid remnants, blood, and red marrow for those patients that had a successful ablation compared to those with a failed ablation (p = 0.030, p = 0.043 and p = 0.048, respectively). The difference between the PBI values acquired at day 1 and day 6 were also indicative of response (p = 0.074). CONCLUSIONS: A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity.
PURPOSE: The aim of this study was to determine the range of absorbed doses delivered to thyroid remnants, blood, and red marrow from fixed administrations of radioiodine and to ascertain whether the success of ablation is more dependent on these absorbed doses than on the administered activity. METHODS: Twenty-three patients received 3,000 MBq radioiodine following near-total thyroidectomy. The maximum absorbed dose to remnants was calculated from subsequent single photon emission tomography scans. Absorbed doses delivered to blood and red marrow were calculated from blood samples and from whole-body retention measurements. The protein bound iodine (PBI) was also calculated. RESULTS: Maximum absorbed doses to thyroid remnants ranged from 7 to 570 Gy. Eighteen of the 23 patients had a successful ablation. A significant difference was seen between the absorbed doses delivered to thyroid remnants, blood, and red marrow for those patients that had a successful ablation compared to those with a failed ablation (p = 0.030, p = 0.043 and p = 0.048, respectively). The difference between the PBI values acquired at day 1 and day 6 were also indicative of response (p = 0.074). CONCLUSIONS: A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle Journal: Thyroid Date: 2006-02 Impact factor: 6.568
Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Yuni K Dewaraja; Scott J Wilderman; Michael Ljungberg; Kenneth F Koral; Kenneth Zasadny; Mark S Kaminiski Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057
Authors: M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri Journal: Eur J Nucl Med Mol Imaging Date: 2008-10 Impact factor: 9.236
Authors: Sarah J Chittenden; Brenda E Pratt; Kay Pomeroy; Peter Black; Clive Long; Nicholas Smith; Susan E Buckley; Frank H Saran; Glenn D Flux Journal: Cancer Biother Radiopharm Date: 2007-04 Impact factor: 3.099
Authors: C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640
Authors: Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-11 Impact factor: 9.236
Authors: Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg Journal: Nat Rev Endocrinol Date: 2011-08-09 Impact factor: 43.330
Authors: Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-06 Impact factor: 9.236
Authors: Klaus Schomäcker; Ferdinand Sudbrock; Thomas Fischer; Markus Dietlein; Carsten Kobe; Mark Gaidouk; Harald Schicha Journal: Eur J Nucl Med Mol Imaging Date: 2011-08-17 Impact factor: 9.236
Authors: Lidia Strigari; Mark Konijnenberg; Carlo Chiesa; Manuel Bardies; Yong Du; Katarina Sjögreen Gleisner; Michael Lassmann; Glenn Flux Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-11 Impact factor: 9.236
Authors: Seong Young Kwon; Sang-Woo Lee; Eun Jung Kong; Keunyoung Kim; Byung Il Kim; Jahae Kim; Heeyoung Kim; Seol Hoon Park; Jisun Park; Hye Lim Park; So Won Oh; Kyoung Sook Won; Young Hoon Ryu; Joon-Kee Yoon; Soo Jin Lee; Jong Jin Lee; Ari Chong; Young Jin Jeong; Ju Hye Jeong; Young Seok Cho; Arthur Cho; Gi Jeong Cheon; Eun Kyoung Choi; Jae Pil Hwang; Sang Kyun Bae Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-10 Impact factor: 9.236